TL;DR
This paper introduces TAGs-seq, a novel method that simultaneously detects both monogenic diseases and chromosomal aneuploidies in embryos during preimplantation genetic testing (PGT). This integrated approach streamlines the process, offering a more comprehensive assessment for embryo selection without a significant increase in sequencing costs.
What Problem Does This Paper Address?
Preimplantation genetic testing for monogenic diseases (PGT-M) is crucial for preventing the transmission of inherited genetic disorders to offspring. However, embryos identified as free of a specific monogenic disease through PGT-M can still harbor chromosomal abnormalities, known as aneuploidies. These aneuploidies can lead to implantation failure, miscarriage, or the birth of a child with developmental issues. Current practices often require separate tests for monogenic diseases (PGT-M) and aneuploidies (PGT-A), making the process more complex, time-consuming, and expensive. This paper addresses the need for a single, efficient method that can reliably detect both types of genetic issues simultaneously, improving the accuracy and comprehensiveness of embryo selection for in vitro fertilization (IVF).
Methods
The core innovation is the TAGs-seq (Targeted And Genome-wide Simultaneous Sequencing) method. This technique integrates two distinct sequencing strategies into a single library preparation workflow:
- Low-pass Whole Genome Sequencing (WGS): This part of the process generates reads that cover the entire genome at a low depth. These reads are primarily used for detecting chromosomal imbalances, such as aneuploidies and copy number variations (CNVs).
- High-depth Target Enrichment Sequencing (TES): This component focuses on specific regions of interest, in this case, the HBB gene (associated with β-thalassemia) and nearby single nucleotide polymorphisms (SNPs). These regions are sequenced at a much higher depth, enabling precise detection of monogenic mutations and accurate haplotype analysis.
The library preparation involves a specialized multiplex PCR step integrated into the whole genome amplification process. This allows for the simultaneous amplification of both the genome-wide regions and the targeted regions. The resulting library is then sequenced using a single-step, low-pass WGS and high-depth TES approach.
Datasets
The study utilized two main types of data for validation:
- Cell Line Data: Genomic DNA (gDNA) and multiple displacement amplification (MDA) products from a fibroblast cell line (GM03918) with a known deletion were used to validate the analytical utility of TAGs-seq for detecting single nucleotide variants (SNVs) and copy number variations (CNVs).
- Clinical Embryo Samples: Data from 54 embryos from 8 women undergoing PGT-M for β-thalassemia were used for clinical validation. This involved comparing TAGs-seq results with conventional PGT-M and PGT-A methods (karyomapping or NGS-based).
Key Insights and Ideas
- Unified Approach: The most significant insight is the successful integration of PGT-M and PGT-A into a single, streamlined workflow. This addresses a major bottleneck in current PGT practices.
- Cost-Effectiveness: By utilizing low-pass WGS for aneuploidy detection and high-depth TES for monogenic disease detection within the same experiment, TAGs-seq achieves comprehensive analysis without a dramatic increase in sequencing data output or cost compared to separate tests.
- Improved Accuracy for Monogenic Testing: The high-depth TES for the target gene (HBB) and flanking SNPs allows for both direct genotyping and linkage analysis. This dual approach mitigates issues like allelic drop-out (ADO) and preferential amplification, which can be problematic in single-cell WGA, leading to more reliable monogenic disease diagnosis.
- Comprehensive Embryo Assessment: The ability to simultaneously identify both chromosomal abnormalities and specific genetic mutations provides a more complete picture for embryo selection, potentially increasing the chances of a successful pregnancy with a healthy child.
Key Results
- Cell Line Validation: TAGs-seq demonstrated high accuracy in detecting SNVs and CNVs in cell line DNA and MDA products. Over 90% of sequencing reads covered the whole-genome region at ~0.3-0.4x depth, while ~5.4%-7.3% of reads covered target genes at >10,000x depth.
- Clinical Validation (PGT-M): In the clinical validation with 54 embryos, TAGs-seq achieved 100% consistency with conventional PGT-M methods for detecting β-thalassemia.
- Clinical Validation (PGT-A): TAGs-seq identified genomic imbalances in 18 out of 54 embryos, showing 81.1% consistency with karyomapping results for aneuploidy detection.
- Combined PGT-A/M: When combining both analyses, approximately 36.4% of embryos free of β-thalassemia (including carriers) were found to have chromosomal aneuploidies or CNVs, highlighting the importance of concurrent testing.
Limitations and Future Work
- Retrospective Study: The clinical validation was performed on retrospective embryo samples, and birth outcomes were not available. This limits the ability to definitively assess whether the PGT-A/M results improve implantation and pregnancy outcomes.
- Lack of Golden Standard for Embryo PGT-A: The study acknowledges the absence of a definitive "golden standard" for verifying genomic imbalance results from retrospectively collected embryos, making direct comparison challenging.
- Limited Scope of Chromosomal Abnormalities: The method currently focuses on detecting chromosome copy number variations and does not detect other chromosomal abnormalities like translocations or inversions. Chromosomal mosaicism was also not detected.
- Future Directions: The authors suggest that TES primers can be easily added to the TAGs-seq PGT-A/M procedure to expand its scope to other monogenic diseases. They also propose that an extended TAGs-seq PGT-A/M panel could further reduce costs in clinical practice. Future large-scale clinical validation is needed to confirm its utility.
Summary updated